Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

VNDA stock hub

Vanda Pharmaceuticals Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

VNDAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

377.7M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

VNDA

In the news

Latest news · VNDA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-60.5

P25 -105.6P50 -46.5P75 -3.1

ROIC-191.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All VNDA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

223

Groups with data

Currency

USD

Showing 223 of 223 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001347178
Company name	Vanda Pharmaceuticals Inc.
Country	United States
Country code	US
Cusip	921659108
Employees	533
Employees Change	165%
Employees Change Percent	44.84
Enterprise value	$188.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2006-04-12
Isin	US9216591084
Last refreshed	2026-05-10
Market cap	$377.7M
Market cap category	Small-Cap
Price	$6.28
Price currency	USD
Rev Per Employee	408,596.62x
Sector	Healthcare
Sic	2834
Symbol	VNDA
Website	https://www.vandapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-63.43%
EV Sales Forward	0.72x
EV/Sales	0.87x
FCF yield	-33.71%
P/B ratio	1.35x
P/S ratio	1.73x
PS Forward	1.44x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-73.64%
EBITDA Margin	-69.78%
Gross margin	94.18%
Gross Profit	$205.1M
Gross Profit Growth	7.97%
Gross Profit Growth Q	4.38%
Gross Profit Growth3 Y	-4.2%
Gross Profit Growth5 Y	-2.15%
Net Income	$-239.5M
Net Income Growth Years	0%
Pretax Margin	-68.74%
Profit Margin	-109.99%
Profit Per Employee	$-449,432
ROA	-18.81
Roa5y	-3.29
ROCE	-53.82
ROE	-60.48
Roe5y	-9.16
ROIC	-191.5
Roic5y	-21.57

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-3.11%
Cagr15y	-1.38%
Cagr1y	43.41%
Cagr20y	-2.44%
Cagr3y	-3.32%
Cagr5y	-18.87%
EPS Growth Years	0
Revenue Growth	8.16x
Revenue Growth Q	3.35x
Revenue Growth Quarters	8x
Revenue Growth Years	2x
Revenue Growth3 Y	-5.33x
Revenue Growth5 Y	-2.94x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.41
Assets	$433.5M
Cash	$202.3M
Current Assets	$293.2M
Current Liabilities	$135.6M
Debt	$13.1M
Debt Equity	$0.05
Equity	$280.8M
Liabilities	$152.8M
Long Term Assets	$140.4M
Long Term Liabilities	$17.2M
Net Cash	$189.2M
Net Cash By Market Cap	$50.11
Net Cash Growth	-42.51%
Net Debt Equity	$-0.67
Tangible Book Value	$165.7M
Tangible Book Value Per Share	$2.75
WACC	7.58

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.16
Inventory Turnover	7
Net Working Capital	$-38.7M
Quick ratio	1.91
Working Capital	$157.6M
Working Capital Turnover	$0.94

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.41%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-27.06%
1Y total return	43.38%
200-day SMA	6.16
3Y total return	-9.64%
50-day SMA	7.51
50-day SMA vs 200-day SMA	50over200
5Y total return	-64.84%
All Time High	33.44
All Time High Change	-81.22%
All Time High Date	2018-12-03
All Time Low	0.45
All Time Low Change	1,295.56%
All Time Low Date	2008-12-23
ATR	0.4
Beta	0.65
Beta1y	0.58
Beta2y	0.7
Ch YTD	-28.8
High	6.53
High52	9.94
High52 Date	2026-03-10
High52ch	-36.82%
Low	6.2
Low52	3.81
Low52 Date	2025-05-15
Low52ch	64.87%
Ma50ch	-16.36%
Premarket Change Percent	1.25
Premarket Price	$6.47
Premarket Volume	9,119
Price vs 200-day SMA	1.95%
RSI	36.78
RSI Monthly	50.62
RSI Weekly	47.28
Sharpe ratio	0.78x
Sortino ratio	1.41
Total Return	-1.41%
Tr YTD	-28.8
Tr15y	-18.86%
Tr1m	-15.7%
Tr1w	-10.29%
Tr3m	-17.04%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	1
Analyst Price Target Top	$14
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.66
Earnings Revenue Estimate	54,738,400x
Earnings Revenue Estimate Growth	9.39x
Operating Income	$-160.4M
Operating margin	-73.64
Price target	$14.9
Price Target Change	$137
Price Target Change Top	$123

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	54,199,760%
Float Percent	90.13%
Net Borrowing	-2,358,000
Shares Insiders	4.25%
Shares Institutions	67.2%
Shares Out	60,135,562
Shares Qo Q	0.61%
Shares Yo Y	1.41%
Short Float	10.33%
Short Ratio	3.3
Short Shares	9.31

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-136.4M
Average Volume	1,178,941.8x
Bv Per Share	4.67
CAPEX	$-783,000
Ch10y	-27.06
Ch15y	-18.86
Ch1m	-15.7
Ch1w	-10.29
Ch1y	43.38
Ch20y	-39.03
Ch3m	-17.04
Ch3y	-9.64
Ch5y	-64.84
Ch6m	42.73
Change	-1.72%
Change From Open	-3.24
Close	6.39
Days Gap	1.56
Depreciation Amortization	8,387,000
Dollar Volume	8,222,630.1
Earnings Date	2026-05-06
Earnings Time	amc
EBIT	$-160.4M
EBITDA	$-152M
EPS	$-4.05
F Score	2
FCF	$-127.3M
FCF EV Yield	-67.56x
FCF Per Share	$-2.12
Financing CF	-2,358,000
Fiscal Year End	December
Founded	2,002
Income Tax	$89.8M
Investing CF	71,192,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-12
Ma150	6.69
Ma150ch	-6.07%
Ma20	7.01
Ma20ch	-10.41%
Net CF	-57,762,000
Next Earnings Date	2026-07-30
Open	6.49
Optionable	Yes
Position In Range	24.24
Post Close	6.28
Postmarket Change Percent	3.19
Postmarket Price	$6.48
Ppne	14,065,000
Pre Close	6.39
Price Date	2026-05-08
Ptbv Ratio	2.28
Relative Volume	1.11x
Revenue	217,782,000x
SBC By Revenue	4.16x
Share Based Comp	9,066,000
Tax By Revenue	41.25x
Tr20y	-39.03%
Tr6m	42.73%
Us State	District of Columbia
Volume	1,309,336
Z Score	-0.43

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does VNDA pay a dividend?

Capital-return profile for this ticker.

Performance

VNDA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns VNDA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+67.2%

Float: +90.1% of shares outstanding

Insider ownership

+4.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

VNDA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

36.8

Neutral momentum band

Price vs 200-day MA

+1.9%

50/200-day relationship not available

Beta (5Y)

0.65

Less volatile than the market

Sharpe ratio

0.78

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About VNDA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current VNDA stock rating?

Vanda Pharmaceuticals Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full VNDA analysis?

The full report lives at /stocks/VNDA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for VNDA?

The latest report frames VNDA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the VNDA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.